Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Carisma Therapeutics (CARM) just unveiled an announcement.
Regina Hodits and Björn Odlander are stepping down from the board of Carisma Therapeutics Inc. due to other commitments, with no disagreements cited. They will be replaced by Marella Thorell, who will chair the audit committee, and Dr. David Scadden, who will chair the science committee, both serving until the 2026 annual meeting. They will receive a $40,000 annual cash compensation plus additional fees and stock options, and enter into the company’s standard indemnification agreement. No related party transactions involving the new directors have been disclosed.
See more data about CARM stock on TipRanks’ Stock Analysis page.